• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Cognition Therapeutics, Inc. - Common Stock (NQ:CGTX)

    1.120 +0.080 (+7.69%)
    Streaming Delayed Price Updated: 4:00 PM EST, Feb 25, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 729,327
    Open 1.070
    Bid (Size) 1.100 (1,000)
    Ask (Size) 1.140 (1,000)
    Prev. Close 1.040
    Today's Range 1.060 - 1.135
    52wk Range 0.2223 - 3.830
    Shares Outstanding 88,268,078
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Cognition Therapeutics Extends Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies
    From Cognition Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Cognition Therapeutics Completes Type C Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies
    From Cognition Therapeutics, Inc.
    Via GlobeNewswire

    Performance

    YTD
    -23.8%
    -23.8%
    1 Month
    -18.8%
    -18.8%
    3 Month
    -23.3%
    -23.3%
    6 Month
    -60.8%
    -60.8%
    1 Year
    +99.8%
    +99.8%

    More News

    Read More
    News headline image
    Cognition Therapeutics Publishes Phase 2 Clinical Results Showing Zervimesine’s Potential to Slow the Progression of Dementia with Lewy Bodies
    From Cognition Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Cognition Therapeutics Reaches Full Enrollment in Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies
    From Cognition Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Cognition Therapeutics Presents Phase 3 Plan for Zervimesine (CT1812) in Alzheimer’s Disease at Clinical Trials on Alzheimer’s Disease (CTAD) Conference
    From Cognition Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Cognition Therapeutics Completes Enrollment in Phase 2 Study of Zervimesine (CT1812) in Early Alzheimer’s Disease
    From Cognition Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Cognition Therapeutics Reports Financial Results for the Third Quarter 2025 and Highlights Progress Across Clinical Programs
    From Cognition Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Here are the top movers in Monday's session. ↗
    Via Chartmill
    News headline image
    12 Health Care Stocks Moving In Monday's Intraday Session ↗
    Via Benzinga
    News headline image
    Which stocks are moving on Monday? ↗
    Via Chartmill
    News headline image
    These Were the 5 Top-Performing Stocks in the Nasdaq Composite in August 2025 ↗
    Via The Motley Fool
    Topics Intellectual Property Stocks
    News headline image
    Cognition Therapeutics Closes $30 Million Registered Direct Offering to Two New Fundamental Institutional Investors, Including a Preeminent Global Investment Firm to Support Phase 3 Development of Zervimesine (CT1812)
    From Cognition Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Wondering what's happening in today's pre-market session? ↗
    Via Chartmill
    News headline image
    12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
    Via Benzinga
    News headline image
    Why Snowflake Shares Are Trading Higher By 14%; Here Are 20 Stocks Moving Premarket ↗
    Via Benzinga
    News headline image
    Cognition Therapeutics Announces $30 Million Registered Direct Offering of Common Stock
    From Cognition Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
    Via Benzinga
    News headline image
    The market is filled with gapping stocks in Monday's session. ↗
    Via Chartmill
    News headline image
    What's going on in today's session ↗
    Via Chartmill
    News headline image
    12 Health Care Stocks Moving In Friday's Intraday Session ↗
    Via Benzinga
    News headline image
    Friday's session: top gainers and losers ↗
    Via Chartmill
    News headline image
    12 Health Care Stocks Moving In Thursday's Intraday Session ↗
    Via Benzinga
    News headline image
    Thursday's session: top gainers and losers ↗
    Via Chartmill
    News headline image
    Wednesday's session: gap up and gap down stocks ↗
    Via Chartmill
    News headline image
    What's going on in today's pre-market session ↗
    Via Chartmill

    Frequently Asked Questions

    Is Cognition Therapeutics, Inc. - Common Stock publicly traded?
    Yes, Cognition Therapeutics, Inc. - Common Stock is publicly traded.
    What exchange does Cognition Therapeutics, Inc. - Common Stock trade on?
    Cognition Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Cognition Therapeutics, Inc. - Common Stock?
    The ticker symbol for Cognition Therapeutics, Inc. - Common Stock is CGTX on the Nasdaq Stock Market
    What is the current price of Cognition Therapeutics, Inc. - Common Stock?
    The current price of Cognition Therapeutics, Inc. - Common Stock is 1.120
    When was Cognition Therapeutics, Inc. - Common Stock last traded?
    The last trade of Cognition Therapeutics, Inc. - Common Stock was at 02/25/26 04:00 PM ET
    What is the market capitalization of Cognition Therapeutics, Inc. - Common Stock?
    The market capitalization of Cognition Therapeutics, Inc. - Common Stock is 98.86M
    How many shares of Cognition Therapeutics, Inc. - Common Stock are outstanding?
    Cognition Therapeutics, Inc. - Common Stock has 99M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.